Acute, Migraine

Transparency Market Research United States of America United Kingdom

11.01.2023 - 12:33:27

Acute Migraine Treatment Market Value to Exceed US$ 7.9 Billion by 2031, Reveals Transparency Market Research

Focus on cost-effective treatment for acute migraine is expected to propel demand for new medications and therapies among patientsAsia Pacific is projected to witness significant opportunities in the next few years, driven by rise in patient populationtrends indicate that CGRP antagonists are emerging as an effective and convenient treatment for migraine and symptoms associated with acute migraine headache. Demand for medications that help prevent progression of migraine attacks is likely to create significant revenues for companies in the next few years. The TMR study reveals that surge in adoption of over-the-counter (OTC) pain relievers and prescription medications has propelled revenues of pharmaceutical companies in the market.

Get free PDF Sample Copy of Acute Migraine Treatment Market here (choose the corporate mail ID to receive top attention): https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85296 

Key Findings of Study

Demand for Effective and Affordable Treatments to Drive Revenues: Increase in awareness about various risk factors is a key trend boosting the market outlook. Rise in availability of affordable treatments for migraine is generating substantial revenues for companies in the market. Demand for effective treatments is expected to fuel the development of new therapies that are effective in prevention or treatment of acute migraine attacks. Preventive medications for migraine have gained traction among the patient population.Rise in Prevalence of Migraine Fuels Sales of Oral Medications: Migraine poses a high health burden among patients of all age groups as it is one of the most prevalent neurological disorders. Rise in sales of oral medications can be ascribed to demand for these as the first line of treatment for the condition. Substantial adoption of oral medications as first-line drugs to treat mild or moderate migraine attacks is a case in point. Demand for cost-effective first-line treatments for various symptoms of migraines is expected to create lucrative opportunities for pharmaceutical companies.

Key Drivers

Rise in awareness about the debilitating impact of migraine on patients' quality of life is a key factor driving the acute migraine treatment industry growthHigh prevalence and morbidity of migraine is a key trend that has spurred the need for medications that can prevent or treat the symptoms of a migraine attack. Migraine has been a significant contributor to the disability-adjusted life years lost due to neurological disorders in several countries in the last few years.

Ask for References – https://www.transparencymarketresearch.com/sample/sample.php?flag=ARF&rep_id=85296 

Regional Growth Dynamics

North America held a major share of the global acute migraine treatment market. Its dominance can be ascribed to rise in incidence of migraine. Revenue growth in the region was led by the presence of several globally prominent companies in the region, and substantial R&D on novel treatments has fuelled the growth opportunities in the market in North America.

The market in Asia Pacific is estimated to expand at an attractive CAGR during the forecast period of 2022–2031. The market growth is propelled by substantial demand for the treatment of acute migraine.

Competition Landscape

The landscape of the global acute migraine treatment industry is fragmented due to the presence of several players. Key players strive to expand their product portfolio and engage in mergers and acquisitions in order to gain acute migraine treatment market shares.

Prominent companies operating in the acute migraine treatment market are Hoffmann-La Roche Ltd., AbbVie, Eli Lilly and Company, Allergan Plc, Novartis AG, Merck & Co., Pfizer, Inc., AstraZeneca, Johnson & Johnson, and Teva Pharmaceutical.

Acute Migraine Treatment Market Segmentation

Drug TypeTriptansCGRP AntagonistNSAID DrugsBeta-adrenergic BlockersErgot AlkaloidsOthersRoute of AdministrationOralInjectionOthersDistribution ChannelHospital PharmaciesRetail PharmaciesOnline Pharmacies

Regions Covered

North AmericaEuropeAsia PacificRest of World

Countries Covered

U.S.CanadaGermanyU.K.FranceItalySpainChinaIndiaJapanAustralia & New Zealand

Buy this Premium Research Report | Immediate Delivery Available – https://www.transparencymarketresearch.com/checkout.php?rep_id=85296<ype=S 

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Research Reports by Transparency Market Research:

Inhaled Nitric Oxide Delivery System Market Share from 2022 - 2031

China Plasma Protein Therapeutics Industry Growth from 2022 - 2031

Multiparametric In-vitro Cardiotoxicity Testing Market Growth Report 2022 - 2031

Oral Thin Films Market Size & Share Report, 2022-2031

Consumer Genomics Market Size, Share | Industry Report, 2022-2032

Periodontal Treatment Market Size & Share Report, 2022 - 2031

Ceftriaxone Market Size | Forecast, 2020-2031

Dental Anesthetics Market Growth Report 2022 - 2031

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com 
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.comhttps://www.transparencymarketresearch.com/checkout.php?rep_id=85283<ype=S

Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/acute-migraine-treatment-market-value-to-exceed-us-7-9-billion-by-2031--reveals-transparency-market-research-301718857.html

@ prnewswire.co.uk